Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
D 5.14 -2.84% -0.15
NVAX closed down 2.84 percent on Monday, March 18, 2024, on 36 percent of normal volume.
14 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Bullish Engulfing Bullish -2.84%
Crossed Above 20 DMA Bullish -2.84%
Pocket Pivot Bullish Swing Setup -2.84%
Outside Day Range Expansion -2.84%
Wide Bands Range Expansion -2.84%
Fell Below 20 DMA Bearish 3.21%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 13 hours ago
Down 3% about 13 hours ago
Fell Below 20 DMA about 13 hours ago
Possible NR7 about 15 hours ago
Possible Inside Day about 15 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Novavax, Inc. Description

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Development Infectious Diseases Coronavirus Influenza Vaccines Vaccination Influenza Vaccine Rabies Seasonal Influenza

Is NVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.36
52 Week Low 3.5324
Average Volume 8,864,545
200-Day Moving Average 6.46
50-Day Moving Average 4.59
20-Day Moving Average 5.16
10-Day Moving Average 5.31
Average True Range 0.45
RSI (14) 52.38
ADX 22.42
+DI 26.05
-DI 17.61
Chandelier Exit (Long, 3 ATRs) 4.70
Chandelier Exit (Short, 3 ATRs) 5.27
Upper Bollinger Bands 6.15
Lower Bollinger Band 4.17
Percent B (%b) 0.49
BandWidth 38.41
MACD Line 0.19
MACD Signal Line 0.23
MACD Histogram -0.0419
Fundamentals Value
Market Cap 610.58 Million
Num Shares 119 Million
EPS -6.23
Price-to-Earnings (P/E) Ratio -0.83
Price-to-Sales 0.46
Price-to-Book 49.52
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.55
Resistance 3 (R3) 5.58 5.47 5.48
Resistance 2 (R2) 5.47 5.37 5.46 5.45
Resistance 1 (R1) 5.31 5.31 5.26 5.28 5.43
Pivot Point 5.20 5.20 5.18 5.19 5.20
Support 1 (S1) 5.04 5.10 4.99 5.01 4.85
Support 2 (S2) 4.93 5.04 4.92 4.83
Support 3 (S3) 4.77 4.93 4.80
Support 4 (S4) 4.74